According to IMARC Group’s latest report, titled “Oncology Molecular Diagnostics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026, the global oncology molecular diagnostics market exhibited strong growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of 12.6% during 2021-2026.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Oncology molecular diagnostics are used to detect the presence of cancerous cells by analyzing the biological molecules. Various tests are performed on blood, saliva, and tumor tissue samples to identify and measure specific genetic sequences in DNA, RNA, and cell proteins. Oncology molecular diagnostics assist in early cancer detection and provide required information pertaining to personalized cancer treatment. They are often used in clinical and point-of-care (POC) testing, along with identifying pathogens and infectious diseases present in the donated blood samples in blood banks.
Request Free Sample Report: https://www.imarcgroup.com/oncology-molecular-diagnostics-market/requestsample
Market Trends
The increasing occurrence of oncological disorders due to unhealthy consumer lifestyles, rising geriatric population, and the growing tobacco consumption, is primarily driving the demand for oncology molecular diagnostics. In line with this, the growing need for early and accurate diagnosis, coupled with several advancements in next-generation sequencing (NGS) techniques, further contributes to the market growth. Moreover, the rising prevalence of viral and bacterial infections, along with the expanding number of blood donation campaigns, is further bolstering the demand for oncology molecular diagnostics.
Ask Analyst and Browse Full Report with TOC & List of Figure: https://bit.ly/32fpm4k
List of Key Companies Covered in this Market Report:
- Agilent Technologies Inc. (NYSE: A)
- Abbott Laboratories (NYSE: ABT)
- Bayer AG (ETR: BAYN)
- BD (Becton, Dickinson and Company) (NYSE: BDX)
- Cepheid Inc. (Danaher Corporation)
- Hoffmann-La Roche AG (SWX: RO)
- Hologic Inc.(NASDAQ: HOLX)
- Qiagen N.V. (NYSE: QGEN)
- Siemens Healthcare (ETR: SHL)
- Sysmex Corporation (TYO: 6869)
The report has segmented the market on the basis of cancer type, product, technology, end-user and geography.
Breakup by Cancer Type:
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Liver Cancer
- Lung Cancer
- Blood Cancer
- Others
Breakup by Product:
- Instruments
- Reagents
- Others
Breakup by Technology:
- Polymerase Chain Reaction (PCR)
- In Situ Hybridization
- Chips and Microarrays
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Mass Spectrometry
- DNA and NGS Sequencing
- Transcription Mediated Amplification (TMA)
- Others
Breakup by End-User:
- Hospitals and Clinics
- Reference Laboratories
- Others
Breakup by Geography:
- North America (U.S. & Canada)
- Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
- Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
- Latin America (Brazil, Mexico)
- Middle East & Africa
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021- 2026)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
